A before-and-after photograph cannot tell you how someone’s appetite changed, which medication they received, or whether their weight loss lasted. An AI-generated transformation cannot document a patient’s response at all.
That distinction sits at the center of the questions surrounding VelvetRx, the online prescription brand operated by Rocket Health Inc., whose CEO is advertising entrepreneur Dean Rojas.
An October 2026 investigation by RippedMeOff matched two advertised customer transformations to stock images labeled as AI-generated. It also documented unexplained review totals, unchanging daily treatment-selection figures, and institutional branding that warranted scrutiny.
For people trying to understand weight-loss treatment, the deeper problem is what those signals encourage them to assume: that an impressive-looking result establishes an effective, predictable medical program.
The biology requires considerably more explanation.
What the Transformation Cards Actually Establish
VelvetRx presented “Jasmine,” age 31, with a claimed 54-pound loss, and “Lauren,” age 37, with an 84-pound loss. Both cards paired personal details and treatment timelines with images matching AI-generated listings on Magnific, according to RippedMeOff’s documented comparisons.
Those images establish no treatment history. Whether the accompanying written accounts have a genuine basis remains a separate question for VelvetRx to substantiate.
Even authentic patient photographs would leave important gaps. They cannot establish which intervention caused a change, how representative that result is, or what happened to people who stopped treatment.
The distinction matters because a testimonial offers an individual story. Evidence about treatment requires a defined group, reliable measurements, and an account of outcomes beyond selected successes.
GLP-1 Medicines Change Appetite Signaling
Semaglutide activates the receptor for GLP-1, a hormone involved in appetite and glucose regulation. Tirzepatide activates both GLP-1 receptors and receptors for GIP, another hormone involved in metabolic regulation.
A receptor is a cellular structure that responds to a signal. These medicines affect systems involved in food intake and blood-glucose control. Their prescribing information describes reduced calorie intake, with appetite changes likely contributing to that effect.
This is more specific than the familiar idea of “speeding up metabolism.” Appetite, the energy used by the body, and the handling of glucose are related processes with different measurements.
A person eating less because hunger has changed has not necessarily developed a higher resting metabolic rate. Likewise, a smaller body in a photograph does not demonstrate improved insulin sensitivity.
Understanding the mechanism helps explain why a treatment might work. Human studies establish how much benefit occurred under particular conditions.
Real Weight-Loss Evidence Needs Context
Consider the STEP 1 randomized trial, published in the New England Journal of Medicine. Researchers enrolled 1,961 adults without diabetes who had obesity, or overweight with a related health condition.
Participants received weekly injected semaglutide or placebo, alongside lifestyle support, for 68 weeks. Average weight loss was 14.9% in the semaglutide group and 2.4% in the placebo group.
These findings support a substantial treatment effect. They also describe a specific population, formulation, comparison, and duration. They do not establish the performance of every online program advertising semaglutide.
Percentage change provides context that pounds alone omit. As a simple illustration, losing 40 pounds represents 20% of a 200-pound starting weight but 10% of a 400-pound starting weight.
An average also leaves room for substantial individual variation. It should not be presented as the result everyone will achieve.
The trial recorded unwanted effects, too. Digestive symptoms led 4.5% of semaglutide participants to discontinue treatment, compared with 0.8% receiving placebo. An account of benefit needs that information alongside the weight-loss figure.
Scale Weight Leaves Part of the Story Untold
Weight loss can include changes in fat and lean tissue. The prescribing information for semaglutide and tirzepatide describes greater loss of fat mass than lean mass, rather than loss exclusively from fat.
A transformation photograph cannot separate those components. Nor can it measure strength, blood pressure, glucose control, or the burden of side effects.
Those outcomes answer different questions. A program claiming better metabolic health should identify the measurements supporting that claim. A smaller waist or lower scale reading cannot stand in for every aspect of health.
This is especially relevant when the advertising emphasizes appearance while asking consumers to make a medical decision.
The Exact Medication Matters
VelvetRx’s captured homepage placed broad FDA-approval language above a treatment menu that included oral GLP-1 offerings. That presentation obscures a distinction fundamental to interpreting the research.
FDA approval concerns a particular drug product. A shared ingredient name does not establish that different formulations have equivalent absorption, effects, or regulatory status.
Approved oral semaglutide products exist. Their evidence applies to those products. In a May 2026 notice, the FDA explicitly stated that no tirzepatide product was approved for oral, sublingual, or buccal administration.
Compounded drugs are not FDA-approved. The FDA does not evaluate their safety, effectiveness, or quality before marketing, although lawful compounding can meet particular medical needs.
For readers, the question is concrete: which product was studied, and is that the product being offered?
A result obtained with an injected medicine cannot simply be assigned to an unidentified tablet. That connection needs evidence.
Popularity Claims Cannot Answer Clinical Questions
RippedMeOff reported that VelvetRx, Rejuve Meds, and VivaRX displayed exactly 14,532 reviews. It also documented VelvetRx’s daily selection figures remaining unchanged across checks on different days.
Identical totals alone do not prove fabricated reviews. Their unexplained presentation does leave readers unable to assess whose experiences they represent.
The investigation further reported that Stanford’s trademark representatives denied an affiliation with VelvetRx despite its logo appearing on the website.
These signals may reassure a visitor, but none measures treatment response. Even an accurately counted review collection would not reveal average weight change, discontinuation rates, or longer-term outcomes unless those data were actually collected.
A useful distinction is between everyone who started a program and only those who completed it. Reporting results from the second group can leave out people who stopped because treatment was ineffective, unaffordable, or difficult to tolerate. A credible outcome claim explains who was included, who was missing, and how missing measurements were handled. A large review count provides none of that information.
Rojas’s performance-marketing background makes the operation’s emphasis on persuasive presentation relevant. The scientific question remains whether the claims accurately describe documented patient experience.
What Happens After the “After” Picture?
A transformation has a chosen endpoint. Weight regulation continues beyond it.
In the STEP 1 extension, researchers followed a subset of 327 participants after medication and structured lifestyle support ended. Over the following year, participants previously receiving semaglutide regained about two-thirds of their earlier weight loss, on average. Several improvements in cardiometabolic measures also moved back toward their starting levels.
The follow-up was exploratory, involved a subset, and ended both interventions. It does not show that everyone will regain the same amount or isolate medication withdrawal from the loss of structured support.
It does show why a photograph taken during treatment cannot establish a lasting outcome.
VelvetRx’s marketing should be judged against questions that matter beyond a signup: what product patients receive, what results are documented, how adverse effects are tracked, and what follow-up supports the advertised benefits.
People considering treatment deserve realistic expectations about a biological process that continues long after the advertisement ends.